New NCCN guidelines include expanded genetic risk assessment for various cancers

The National Comprehensive Cancer Network (NCCN)-;an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care-;announces the publication of the expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate.

The 9th Joint ECTRIMS-ACTRIMS Meeting – Biotech Investments

Issuer: Immunic, Inc. / Key word(s): Study results/Conference 11.10.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Presents

October 12, 2023

APCO Annual Report & Action Plan

September 23, 2024

GSK bullish on RSV vaccine battle against Pfizer, ships first Arexvy dose

GSK is bullish about the market prospects for its RSV vaccine Arexvy in older adults. The Big Pharma has already shipped its first doses to

July 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.